Why is Concord Drugs falling/rising?

As of 30-Jun, Concord Drugs Ltd is experiencing a significant rise in its stock price, currently at Rs 41.36, which reflects an increase of Rs 5.36 or 14.89%. The stock has been gaining momentum, having outperformed its sector by 14.2% today and achieving a remarkable 33.42% return over the last three days. It is also close to its 52-week high, just 1.55% away, and has shown strong performance over various time frames, including a 37.91% increase over the past week. However, despite these positive movements, the company has reported a decline in profits of -13% over the past year, and its long-term fundamentals show weak growth in operating profits, which may temper investor enthusiasm.
In the broader market context, Concord Drugs' short-term performance stands in stark contrast to the Sensex, which has only risen by 2.09% over the past week. This indicates that the stock is not only gaining traction independently but is also attracting increased investor participation, as evidenced by a significant rise in delivery volume. While the stock is trading at a discount compared to its peers and has an attractive valuation, the underlying concerns regarding its ability to service debt and low profitability per unit of shareholders' funds may pose risks to its continued ascent. Overall, the stock's recent rise can be attributed to strong short-term performance and investor interest, despite the backdrop of longer-term challenges.